Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer
出版年份 2013 全文链接
标题
Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer
作者
关键词
-
出版物
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 77, Issue 4, Pages 695-703
出版商
Wiley
发表日期
2013-08-22
DOI
10.1111/bcp.12229
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial
- (2013) V. O. Dezentjé et al. BREAST CANCER RESEARCH AND TREATMENT
- Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer
- (2013) Pilar H Saladores et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Reply to A.-S. Dieudonné et al and J.M. Rae et al
- (2013) Hiltrud Brauch et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
- (2013) Ulrich M. Zanger et al. PHARMACOLOGY & THERAPEUTICS
- Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed
- (2013) H. L. McLeod SCIENCE
- Personalized medicine: is it a pharmacogenetic mirage?
- (2012) Rashmi R. Shah et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8
- (2012) M. P. Goetz et al. CLINICAL CANCER RESEARCH
- Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters
- (2012) Hiltrud Brauch et al. JOURNAL OF CLINICAL ONCOLOGY
- Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial and Re: CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
- (2012) P. D. P. Pharoah et al. JNCI-Journal of the National Cancer Institute
- Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Y. Nakamura et al. JNCI-Journal of the National Cancer Institute
- Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) V. Stanton JNCI-Journal of the National Cancer Institute
- CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
- (2012) James M. Rae et al. JNCI-Journal of the National Cancer Institute
- CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Meredith M. Regan et al. JNCI-Journal of the National Cancer Institute
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
- (2012) Christina Davies et al. LANCET
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma
- (2011) T E Mürdter et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
- (2011) L Madlensky et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study
- (2011) William J. Irvin et al. JOURNAL OF CLINICAL ONCOLOGY
- CYP2D6 Polymorphisms as Predictors of Outcome in Breast Cancer Patients Treated with Tamoxifen: Expanded Polymorphism Coverage Improves Risk Stratification
- (2010) W. Schroth et al. CLINICAL CANCER RESEARCH
- American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
- (2010) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical Relevance
- (2010) Michaela J. Higgins et al. Current Oncology Reports
- The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor for Degradation in Breast Cancer Cells
- (2009) X. Wu et al. CANCER RESEARCH
- A Century of Deciphering the Control Mechanisms of Sex Steroid Action in Breast and Prostate Cancer: The Origins of Targeted Therapy and Chemoprevention
- (2009) V. Craig Jordan CANCER RESEARCH
- Pharmacogenomics of Tamoxifen Therapy
- (2009) H. Brauch et al. CLINICAL CHEMISTRY
- Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: The ‘personalised’ approach?
- (2009) Hiltrud Brauch et al. EUROPEAN JOURNAL OF CANCER
- Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
- (2009) Werner Schroth JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Genotype-guided tamoxifen therapy: time to pause for reflection?
- (2009) Timothy L Lash et al. LANCET ONCOLOGY
- Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram
- (2008) T L Lash et al. BRITISH JOURNAL OF CANCER
- Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer
- (2008) V. O. Dezentje et al. CLINICAL CANCER RESEARCH
- Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer
- (2008) L. W. M. Loo et al. GENES CHROMOSOMES & CANCER
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
- (2008) LANCET ONCOLOGY
- Tamoxifen: Catalyst for the change to targeted therapy
- (2007) V. Craig Jordan EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now